Thalassemia and Sickle Cell Patients in the UK Gain Access to Blood Transfusion Test to Reduce Side Effects
source: pixabay.com

Thalassemia and Sickle Cell Patients in the UK Gain Access to Blood Transfusion Test to Reduce Side Effects

People living with blood disorders like sickle cell disease or thalassemia will now have access to a new blood test that will reduce transfusion side effects. England’s National Health Service…

Continue Reading Thalassemia and Sickle Cell Patients in the UK Gain Access to Blood Transfusion Test to Reduce Side Effects
Guideline-Based Care Might Reduce Cerebrovascular Illness in Sickle Cell Disease
source: shutterstock.com

Guideline-Based Care Might Reduce Cerebrovascular Illness in Sickle Cell Disease

According to a story from Healio, a recent study has found that use of hydroxyurea in alignment with treatment guidelines has the potential to bring down symptoms of cerebrovascular disease…

Continue Reading Guideline-Based Care Might Reduce Cerebrovascular Illness in Sickle Cell Disease
U.K. Health Authorities Grant Approval for a New Medicine using CRISPR Gene Editing to Treat Beta thalassemia and Sickle Cell
source: shutterstock.com

U.K. Health Authorities Grant Approval for a New Medicine using CRISPR Gene Editing to Treat Beta thalassemia and Sickle Cell

CRISPR was first described ten years ago as a viral mechanism for defense, taken from bacteria, which could be transformed into genetic scissors and accurately alter DNA. About Casgevy CRISPR…

Continue Reading U.K. Health Authorities Grant Approval for a New Medicine using CRISPR Gene Editing to Treat Beta thalassemia and Sickle Cell
A Preview of Potentially Historic FDA Approvals for 2023
source: shutterstock.com

A Preview of Potentially Historic FDA Approvals for 2023

  The later part of 2023 will see decisions on drugs in four areas such as advanced melanoma, sickle cell disease, Alzheimer’s disease, and depression. BioSpace shines the spotlight on…

Continue Reading A Preview of Potentially Historic FDA Approvals for 2023
Study of the Week: Hydroxyurea Underused in Pediatric Sickle Cell Anemia Patients Despite Recommendations
source: pixabay.com

Study of the Week: Hydroxyurea Underused in Pediatric Sickle Cell Anemia Patients Despite Recommendations

Welcome to Study of the Week from Patient Worthy. In this segment, we select a study we posted about from the previous week that we think is of particular interest…

Continue Reading Study of the Week: Hydroxyurea Underused in Pediatric Sickle Cell Anemia Patients Despite Recommendations
Biologics License Application (BLA): Lovo-cel Gene Therapy for SCD Just Submitted 
https://pixabay.com/en/heart-red-blood-cells-erythrocyte-2176218/

Biologics License Application (BLA): Lovo-cel Gene Therapy for SCD Just Submitted 

  As bluebird bio ("bluebird") waited on FDA feedback regarding the manufacturing process for lovotibeglogene autotemcel (lovo-cel) genetherapy, the company disclosed that it would most likely miss its Q1 submission…

Continue Reading Biologics License Application (BLA): Lovo-cel Gene Therapy for SCD Just Submitted 
NFL Player Tevin Coleman Discusses Daughter’s Sickle Cell Disease (SCD) Diagnosis
https://pixabay.com/en/heart-red-blood-cells-erythrocyte-2176218/

NFL Player Tevin Coleman Discusses Daughter’s Sickle Cell Disease (SCD) Diagnosis

  On the field, Running Back (RB) Tevin Coleman has done some amazing things. He has played in 94 games, gained 3,319 rushing yards, and scored 25 touchdowns. Off the…

Continue Reading NFL Player Tevin Coleman Discusses Daughter’s Sickle Cell Disease (SCD) Diagnosis
Promising Research Results from the 64th ASH Annual Meeting
source: pixabay.com

Promising Research Results from the 64th ASH Annual Meeting

The 64th ASH Annual Meeting held on December 10, 2022, focused on various approaches for hematologic diseases with the goal of improving quality care and outcomes. Dr. Stephanie Lee, of…

Continue Reading Promising Research Results from the 64th ASH Annual Meeting
Study of the Week: Nearly a Fifth of Sickle Cell Disease Patients May Develop Craniosynostosis
source: pixabay.com

Study of the Week: Nearly a Fifth of Sickle Cell Disease Patients May Develop Craniosynostosis

Welcome to Study of the Week from Patient Worthy. In this segment, we select a study we posted about from the previous week that we think is of particular interest…

Continue Reading Study of the Week: Nearly a Fifth of Sickle Cell Disease Patients May Develop Craniosynostosis

Editor’s Choice: A New Dystonia Center of Excellence, A Call for Sickle Cell Blood Donors, and a New Treatment Target for Glioblastoma

Happy Friday! A tropical storm system will be traveling up through the mid-Atlantic this weekend, bringing wind and rain. Hunker down! This week, we have stories on Duke University being…

Continue Reading Editor’s Choice: A New Dystonia Center of Excellence, A Call for Sickle Cell Blood Donors, and a New Treatment Target for Glioblastoma

Two Novel Sickle Cell Disease Treatments Have Received Orphan Drug and Rare Pediatric Disease Designation

Global Blood Therapeutics (GBT) has just announced that their therapeutics called GBT021601 (GBT601) and inclacumab for sickle cell disease (SCD) have received both Rare Pediatric Disease Designation and Orphan Drug…

Continue Reading Two Novel Sickle Cell Disease Treatments Have Received Orphan Drug and Rare Pediatric Disease Designation